Halozyme Provides 2020 Guidance Highlighted By Strong Revenue, EPS Growth

 - 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue -

- 2021 Royalties Projected to Double versus Expected 2020 Royalties -

- 2021 EPS Guidance of $1.40 to $1.55 Representing 55%-70% Growth over Expected 2020 EPS -

Anticipated 2021 Key Events :

• Strong subcutaneous DARZALEX® (daratumumab) royalty revenue growth driven by continued US and international market uptake;
• Potential Ministry of Health, Labour and Welfare approval in Japan for Janssen's subcutaneous DARZALEX® utilizing ENHANZE®;
• Potential U.S. FDA approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in light chain amyloidosis;
• Strong Phesgo® (pertuzumab, trastuzumab and hyaluronidase) royalty revenue growth driven by adoption in US and Europe;
• Two new products entering Phase 3 development, resulting in a total of 4 products in Phase 3, including Roche's TECENTRIQ® (atezolizumab) and argenx's efgartigimod;
• Five new Phase 1 trial starts for ENHANZE® partner programs resulting in a total of 13 Phase 1 studies completed or ongoing by end of 2021;
• Continued commitment to capital return with up to $125 million in share repurchases anticipated in 2021 as part of the $550 million three-year share repurchase plan authorized by Halozyme's board of directors in November 2019.

JPMorgan link: https://www.prnewswire.com/news-releases/halozyme-to-present-virtually-at-the-39th-annual-jp-morgan-healthcare-conference-301198210.html

https://www.prnewswire.com/news-releases/halozyme-provides-2021-financial-guidance-highlighted-by-strong-revenue-and-eps-growth-301204808.html